DBV Technologies (DBVT) Total Current Liabilities (2015 - 2026)
DBV Technologies (DBVT) posted quarterly Total Current Liabilities of $54.3 million for Q2 2026, up 9.86% year-on-year from $49.4 million in Q2 2025, and up 4.83% on a QoQ basis from $51.8 million in Q1 2026.
DBV Technologies (DBVT) Total Current Liabilities (2015 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Total Current Liabilities for 12 consecutive years, with $54.3 million the latest figure, recorded in Q2 2026.
- Quarterly Total Current Liabilities rose 9.86% year-over-year to $54.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $54.3 million (up 9.86% YoY) and the FY2025 annual result came in at $58.0 million, up 86.28% from the prior year.
- Total Current Liabilities advanced to $54.3 million in Q2 2026 per DBVT's latest filing, from $51.8 million in the prior quarter.
- Over the last five years, Total Current Liabilities for DBVT reached as high as $58.0 million in Q4 2025 and fell as low as $26.0 million in Q1 2022.
- A 5-year average of $37.1 million and a median of $32.1 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities tumbled 32.96% — and 2025, when it jumped 86.28%.
- Year by year, Total Current Liabilities stood at $29.5 million in 2022, then rose by 26.48% to $37.3 million in 2023, then retreated by 16.61% to $31.1 million in 2024, then surged by 86.28% to $58.0 million in 2025, then fell by 6.38% to $54.3 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $54.3 million, $51.8 million, and $58.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | 54.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.30 Mn |
| Mar 31, 2026 | 51.80 Mn |
| Dec 31, 2025 | 58.00 Mn |
| Sep 30, 2025 | 49.49 Mn |
| Jun 30, 2025 | 49.43 Mn |
| Mar 31, 2025 | 40.38 Mn |
| Dec 31, 2024 | 31.14 Mn |
| Sep 30, 2024 | 30.91 Mn |
| Jun 30, 2024 | 27.38 Mn |
| Mar 31, 2024 | 26.48 Mn |
| Dec 31, 2023 | 37.34 Mn |
| Sep 30, 2023 | 31.44 Mn |
| Jun 30, 2023 | 33.37 Mn |
| Mar 31, 2023 | 32.78 Mn |
| Dec 31, 2022 | 29.52 Mn |
| Sep 30, 2022 | 28.39 Mn |
| Jun 30, 2022 | 30.43 Mn |
| Mar 31, 2022 | 26.03 Mn |
| Dec 31, 2021 | 31.40 Mn |
| Sep 30, 2021 | 33.81 Mn |